MP George Freeman says the failed Pfizer bid for Astrazeneca is not a lost opportunity.
Instead, it ensures a focus on the crusade to make the UK a hub for medicine design.
Freeman says the UK must look to its public health service to boost research.
That will ensure the debate continues to be around doing business in the UK.
